RDD 2021 Program Presentation: Locally administered biologics are of great interest for the treatment of lung diseases, but the development of shelf-stable, dry-powder formulations for inhalation has remained a challenge. This work describes manufacture of a monoclonal antibody (mAb) as a stable, respirable, biologically active pulmonary formulation using spray drying.  A case study is presented.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center